EA202190041A1 - DOSING SCHEDULES FOR ADC K CD19 ADMINISTRATION - Google Patents

DOSING SCHEDULES FOR ADC K CD19 ADMINISTRATION

Info

Publication number
EA202190041A1
EA202190041A1 EA202190041A EA202190041A EA202190041A1 EA 202190041 A1 EA202190041 A1 EA 202190041A1 EA 202190041 A EA202190041 A EA 202190041A EA 202190041 A EA202190041 A EA 202190041A EA 202190041 A1 EA202190041 A1 EA 202190041A1
Authority
EA
Eurasian Patent Office
Prior art keywords
adc
administration
dosing schedules
adcs
relates
Prior art date
Application number
EA202190041A
Other languages
Russian (ru)
Inventor
Джей Маршалл Фейнголд
Дэвид Родни Унгар
Original Assignee
Адс Терапьютикс Са
Медимьюн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адс Терапьютикс Са, Медимьюн Лимитед filed Critical Адс Терапьютикс Са
Priority claimed from PCT/EP2018/065873 external-priority patent/WO2018229222A1/en
Publication of EA202190041A1 publication Critical patent/EA202190041A1/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к лечению патологических состояний, таких как рак, с применением конъюгатов антитело-лекарственное средство (ADC). В частности, настоящее изобретение относится к введению ADC, которые связываются с CD19 (CD19-ADC).The present invention relates to the treatment of pathological conditions such as cancer using antibody-drug conjugates (ADCs). In particular, the present invention relates to the administration of ADCs that bind to CD19 (CD19-ADC).

EA202190041A 2018-05-23 2018-06-14 DOSING SCHEDULES FOR ADC K CD19 ADMINISTRATION EA202190041A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1808473.1A GB201808473D0 (en) 2018-05-23 2018-05-23 Dosage regime
PCT/EP2018/065873 WO2018229222A1 (en) 2017-06-14 2018-06-14 Dosage regimes for the administration of an anti-cd19 adc

Publications (1)

Publication Number Publication Date
EA202190041A1 true EA202190041A1 (en) 2021-04-16

Family

ID=62812164

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190041A EA202190041A1 (en) 2018-05-23 2018-06-14 DOSING SCHEDULES FOR ADC K CD19 ADMINISTRATION

Country Status (2)

Country Link
EA (1) EA202190041A1 (en)
GB (1) GB201808473D0 (en)

Also Published As

Publication number Publication date
GB201808473D0 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
MX371092B (en) Peptidomimetic compounds and antibody-drug conjugates thereof.
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
CY1121517T1 (en) NON-FUCUCYLIZED ANTIBODIES ENANTI-FGFR2IIIB
ZA201907613B (en) Dosage regimes for the administration of an anti-cd19 adc
EA201692002A1 (en) STABLE COMPOSITIONS FOR ANTIBODIES TO CD19 AND CONJUGATES ANTIBODECASTIC MEDICINE
PH12016500375A1 (en) Engineered anti-dll3 conjugates and methods of use
SA519402159B1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201692530A1 (en) CYTOTOXIC PEPTIDES AND THEIR CONJUGATES
IN2012DN03112A (en)
EA201691845A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA202090204A1 (en) ANTI-CD137 ANTIBODIES
EA201691844A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2018015274A (en) Anti-cd98 antibodies and antibody drug conjugates.
TN2015000377A1 (en) Pan-elr+ cxc chemokine antibodes
MX2019014923A (en) Dosage regimes for the administration of an anti-cd25 adc.
PL423259A1 (en) Antibody-urease conjugates for therapeutic purposes
EA201991196A1 (en) SELF-ASSEMBLED DIBLO-COPOLYMERS CONSISTING OF PEGMEMA AND CARRYING MEDICINE OF POLYMERIC SEGMENTS
EA201992318A1 (en) COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING A MOLECULE BINDING PROGASTRIN
MX2020003089A (en) Thailanstatin analogs.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
MX2019008773A (en) Calicheamicin derivatives and antibody drug conjugates thereof.
MX2022001731A (en) Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins.
EA202190041A1 (en) DOSING SCHEDULES FOR ADC K CD19 ADMINISTRATION